The week's most consequential number was a null one: a decade-long follow-up that found no survival benefit from early stenting in stable heart disease. Set against it, Innovent's 65% LDL-C cut looks less like a breakthrough than a milestone — China now has the data to file. Everything else here is the machinery that decides whether either fact changes anything.
Early heart procedures show no survival gain in stable disease
Nearly ten years on, the ISCHEMIA follow-up reports 26% mortality with early invasive care against 27% with medication and lifestyle alone. Anyone who assumed stents buy survival in stable disease should read this twice; it is the finding most likely to change practice and spending.
SINTBILO cuts LDL-C 65% in Phase 3 monotherapy trial, Innovent says
Innovent's anti-PCSK9 antibody hit its primary endpoint as a stand-alone therapy in Phase 3 and is already lining up another filing. The efficacy is roughly what incumbent PCSK9 drugs deliver — what is new is that a Chinese developer now has the data to compete, which is how this market gets repriced.
Clean tech cuts oil-shock GDP hit by 0.25 points, S&P Global finds
S&P Global estimates clean tech cushioned the GDP hit from an oil shock by a quarter point, with EVs displacing 1.9 million barrels a day in 2026. The warning matters as much as the headline: the shift redistributes dependence toward China rather than ending it.
Fibocom modules register on SpaceX DTC network in New Zealand test
Fibocom's modules pulled roughly 2.2 Mbps from SpaceX's direct-to-cell network in open-sky testing without satellite-specific hardware changes. If that survives scale, satellite coverage stops being something device makers design in and becomes something they inherit.
Robbyant open-sources LingBot-Touch, a tactile model for robot hands
LingBot-Touch is a tactile foundation model trained on nearly 5,000 hours of touch, built so different hands and action models can share what they learn. Open-sourcing it is a credible bid to do for robotic touch what shared vision datasets did for perception.
LG wins first ASIL D central gateway certification
TÜV Rheinland issued product-level ASIL D certification for LG's central gateway built for the Genesis GV90, a first for both organisations in the category. Functional safety sign-off, not chip specifications, is where software-defined vehicles actually stall — which makes a certification story worth more attention than it usually gets.
Read the two clinical stories together: one shows how quickly Chinese biotech has closed the gap, the other how much evidence is still needed before acting on a number.